Multiple Myeloma: International Myeloma Foundation : •health professionals   : webcasts

Bringing the Experts to You

The IMF is pleased to provide you with a broad sampling of myeloma presentations and posters from the 2004 annual meeting of the American Society of Hematology in San Diego, California. We hope you will find this material informative and useful.

share |

ASH 2004 Presentations and Posters

THERAPIES FOR PREVIOUSLY UNTREATED PATIENTS

ASH 2004: Assoc. Prof. S.Vincent Rajkumar, MD

Combination Therapy with CC-5013 (Lenalidomide; RevlimidTM) plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma

A Randomized Phase III Trial of Thalidomide Plus Dexamethasone Versus Dexamethasone in Newly Diagnosed Multiple Myeloma (E1A00): A Trial Coordinated by the Eastern Cooperative Oncology Group

ASH 2004: Sundar Jagannath, MD

Bortezomib as First-Line Therapy in Patients with MM; A Multicenter Phase 2 Clinical Trial

ASH 2004: Paul G. Richardson, MD

Phase 2 Clinical Trial of Single Agent Bortezomib in Patients with Previously Untreated Multiple Myeloma.

ASH 2004: Prof. Thierry Facon, MD

Randomized Trial Comparing MP, MP-THAL and MEL100 for Newly Diagnosed Pts Aged 65-75 Years

ASH 2004: Asst. Prof. Michael Wang, MD

VTD (Velcade, Thalidomide, Dexamethasone) as Primary Therapy for Newly-Diagnosed Multiple Myeloma.

ASH 2004: Prof. Jesus San Miguel

A Phase I/II National Multicenter Open-label Study of Bortezomib Plus Melphalan and Prednisone in Elderly Untreated Multiple Myeloma Patients

ASH 2004: Prof. Meletios-Athanassios Dimpopoulos, MD

Primary Treatment with Pulsed Melphalan, Dexamethasone, Thalidomide (MDT) for Symptomatic Patients with Multiple Myeloma Who Are 75 Years of Age or Older.

ASH 2004: Prof. Morie A. Gertz, MD

A Randomized Phase III Trial of Thalidomide Plus Dexamethasone Versus Dexamethasone in Newly Diagnosed Multiple Myeloma (E1A00)

A new trial (E4A03) just opening to look at Revlimid vs. Thalidomide and standard dose vs. lower dose Dexamethasone

ASH 2004: Antonio Palumbo, MD

MPT vs MP: INTERIM ANALYSIS PROSPECTIVE RANDOMIZED TRIAL NEWLY DIAGNOSED PATIENTS AGE > 65 YEARS

THERAPIES FOR RELAPSING PATIENTS

ASH 2004: Rubin Niesvizky, MD

Depsipeptide in the Treatment of Relapsed and Refractory Multiple Myeloma (MM): A Prospective Evaluation of the Cell Cycle

ASH 2004: Antonio Palumbo, MD

THAL + DEX IS EFFECTIVE SALVAGE REGIMEN FOR PTS RELAPSING AFTER AUTOLOGOUS TRANSPLANT

ASH 2004: Paul G. Richardson, MD

Bortezomib vs High-Dose Dexamethasone in Relapsed Multiple Myeloma: Results of a Large Randomized Phase 3 Study

NEW AGENTS, SUPPORTIVE CARE, PROGNOSTIC FACTORS, AND MOLECULAR BIOLOGY

ASH 2004: Prof. Brian G.M. Durie, MD

Osteonecrosis of the Jaw In Myeloma:Time Dependent Correlation with AREDIA and ZOMETA Use

ASH 2004: Prof. Heinz Ludwig

Poorer Survival in Multiple Myeloma Correlates with Patients’ age and is Linked to a Higher Stage at Presentation but Prognostic Parameters Reflecting the Biology of the Myeloma Clone are not Associated with Age.

ASH 2004: Asst. Prof. Rafael Fonseca, MD

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16;q32) and -17p13 (p53) deletions in myeloma patients treated with high dose therapy.

ASH 2004: Mohamad Hussein, MD

A Phase I, Multi-Dose Study of SGN-40 (anti-huCD40 mAb) in Patients with MM

ASH 2004: Asst. Prof. William F. Matsui, MD and Carol Ann Huff, MD

Antibody-Based Therapy Targeting Myeloma Stem Cells

Meral Beksac, MD

[4869] IL-101082-A and TNF-Alpha 238/308A Genotypes Are Associated with Earlier (Younger than 55) Onset of Multiple Myeloma.

ASH 2004: Prof. John DiPersio, MD, PhD

A Pilot Study Evaluating the Safety and Efficacy of AMD3100 for the Mobilization and Transplantation of HLA-Matched Sibling Donor HematopoieticStem Cells in Patients with Advanced Hematological Malignancies.